ストックスクリーナーアプリを入手
4.77
0.63%
0.03
アフターアワーズ：
4.81
0.04
+0.84%
Polypid Ltd (PYPD) 最新ニュース
AIGH Capital Management LLC Purchases Shares of 1,504,741 PolyPid Ltd. $PYPD - MarketBeat
PolyPid Ltd (PYPD) Stock News Today - TradingKey
Conferencia de resultados del 2T de 2026 de PolyPid (PYPD): revisión prioritaria de D-PLEX100 y acuerdo con Azurity - TradingKey
What is HC Wainwright's Forecast for PolyPid Q3 Earnings? - MarketBeat
PolyPid (PYPD) Earnings Call zum 2. Quartal 2026: Prioritäre Prüfung für D-PLEX100 und Azurity-Deal - TradingKey
Roth MKM Maintains PolyPid(PYPD.US) With Buy Rating, Cuts Target Price to $8 - Moomoo
PolyPid (PYPD) investors disclose up to 13.4% beneficial stake via complex structure - Stock Titan
HC Wainwright Issues Negative Estimate for PolyPid Earnings - MarketBeat
PolyPid Earnings Call: Priority Review, Big Azurity Deal - TipRanks
PolyPid Ltd (PYPD) (Q2 2026) Earnings Call Highlights: FDA Priority Review and $30M Azurity ... - Yahoo Finance
PolyPid Posts Wider H1 2026 Loss as Assets and Equity Decline - TipRanks
PolyPid Ltd. Q2 2026 Earnings Call Summary - Yahoo Finance
PolyPid (PYPD) secures $30M Azurity payments but flags going concern risk - Stock Titan
Transcript : PolyPid Ltd., Q2 2026 Earnings Call, Aug 12, 2026 - marketscreener.com
Rosalind entities (PYPD) report 9.9% PolyPid stake, with 4.56M warrant shares blocked at 9.99% - Stock Titan
PolyPid Releases Q2 2026 Financial Results - news.alphastreet.com
PolyPid (NASDAQ:PYPD) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
PolyPid Q2 Earnings Call Highlights - MarketBeat
PolyPid Q2 losses narrow 55%, FDA accepts D-PLEX100 NDA - scanx.trade
Earnings call transcript: PolyPid narrows loss in Q2 2026 as stock falls premarket - Investing.com Australia
PolyPid Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
PolyPid Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 - marketscreener.com
PolyPid Wins FDA Priority Review for D-PLEX₁₀₀ and Locks In $30 Million Azurity Milestones - TipRanks
PYPD: FDA accepted NDA for D-PLEX 100; $30M milestone secured, cash runway projected into 2028 - tradingview.com
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results - The Manila Times
PolyPid (PYPD) secures D-PLEX100 FDA priority review and $30M Azurity deal - Stock Titan
PolyPid's D-PLEX100 Deal Includes Up to About $320M in Payments - Stock Titan
PolyPid Ltd (PYPD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PolyPid (PYPD) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
PYPD Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Polypid Gains Nda Acceptance and Priority Review for D-Plex100 and Announces Partnership with Azurity Pharmaceuticals - marketscreener.com
PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026 - The Manila Times
PolyPid to Report Second Quarter 2026 Financial Results and Host Conference Call on August 12, 2026 - Quiver Quantitative
PolyPid Schedules 8:30 a.m. Webcast for Aug. 12 Results - Stock Titan
PolyPid stock jumps as FDA accepts D-PLEX100 NDA with priority review By Investing.com - Investing.com South Africa
PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀ - GlobeNewswire
FDA grants priority review to PolyPid's D-PLEX1... - Pluang
PolyPid Ltd (PYPD) Balance Sheet - TradingKey
PolyPid Ltd (PYPD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PYPD|PolyPid Ltd|Price:3.950|Chg%:+0.050 - TradingKey
PYPD|PolyPid Ltd|Price:4.290|Chg%:-0.080 - TradingKey
PolyPid Ltd (PYPD) Earnings Date & Reports & Earnings News - TradingKey
PolyPid Ltd (PYPD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PolyPid Ltd (PYPD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PolyPid Ltd (PYPD) Institutional Confidence - TradingKey
PolyPid Ltd (PYPD) Valuation: PE, PB & Fair Value Analysis - TradingKey
PolyPid Ltd (PYPD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PolyPid Ltd (PYPD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PolyPid Ltd (PYPD) Income Statement - TradingKey
Short Interest in PolyPid Ltd. (NASDAQ:PYPD) Expands By 235.2% - MarketBeat
TradingKey - TradingKey
PYPD|PolyPid Ltd|Price:3.980| - TradingKey
PolyPid, Azurity Sign US$330M Deal for D-PLEX100 - Streetwise Reports
Antibacterial Drug Partnership Accelerates PolyPid Commercial Path - Streetwise Reports
H.C. Wainwright Maintains PolyPid(PYPD.US) With Buy Rating, Maintains Target Price $13 - Moomoo
HC Wainwright Has Optimistic Outlook of PolyPid Q2 Earnings - MarketBeat
H.C. Wainwright reiterates Buy on PolyPid stock, $13 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy on PolyPid stock, $13 target - Investing.com UK
PolyPid price target lowered to $12 from $13 at Craig-Hallum - TipRanks
PYPD Reiterates by HC Wainwright & Co. -- Price Target Maintained at $13 - GuruFocus
Azurity Pharmaceuticals Announces Plans To Commercialize D-PLEX100 In The United States And Canada Through Exclusive Partnership With PolyPid - marketscreener.com
Roth Capital reaffirms Buy on PolyPid after exc... - Pluang
PolyPid, Azurity sign surgical site infection drug deal - Reuters
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):